Skip to content

Psychologic Impact of COVID-19 Pandemic on the Hospital Staff of the Nouvelle Aquitaine Area

Psychologic Impact of COVID-19 Pandemic on the Hospital Staff of the Nouvelle Aquitaine Area : a Prospective Longitudinal Study by Self-administered Questionnaires

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04945837
Acronym
IMPSY-COV
Enrollment
8000
Registered
2021-06-30
Start date
2022-09-30
Completion date
2024-12-31
Last updated
2022-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19, Personnel, Hospital, Work-Related Condition, Work-Related Stress Disorder

Keywords

COVID-19, Mental health, Anxiety, Hospital personnel, Longitudinal, Pandemic

Brief summary

Evaluation of the psychological impact of the COVID-19 pandemic on hospital staff in the French Nouvelle Aquitaine area, through a longitudinal study with repeated self-administered psychologic scales

Detailed description

Evaluation of the psychological impact of Coronavirus disease 2019 (COVID-19) on hospital personnel in Nouvelle Aquitaine. IMPSY-COV Upon recent outbreaks of new diseases (SARS, MERS-CoV, Ebola) have led to the emergence of psychiatric disorders in healthcare workers , such as post-traumatic stress , anxiety (e.g., panic attacks) or depressive episodes. Observed similarities in between propagation patterns of SARS-CoV-2 and SARS, alow us to expect the occurence of similar psychiatric disorders in COVID-19 context to those described (Vignaud, Prieto, 2020). The study is set up to assess the psychological state of hospital personnel in the working conditions of treating COVID-19 suffering patients. 87000 hospital staff workers from the Nouvelle Aquitaine region will be invited to take part in the study. This includes medical and non-medical professionals from general and psychiatric hospitals exposed to COVID-19. Study design. The protocol shows two phases and five measurement timepoints. In the initial phase (T0), eligible persons will be contacted via email. Those wishing to participate will then consent, answer socio-demographic questions and a series of psychology questionnaires. In the longitudinal phase, participants will be again invited to answer the same series of questionnaires four times: one month after the initial phase (T1), 3 months after (T2), 6 months after (T3) and 12 months after (T4). Statistical analysis. In order to identify the consequences generated by COVID-19 in hospital personnel through a longitudinal protocol, several statistical analyses are considered, including logistic and linear regressions as well as ANOVA and MANOVA. Expected outcomes. The study will assess the occurrence and the evolution of psychological distress and identify vulnerability factors that may trigger psychiatric disorders in these situations. The study will also provide an opportunity to improve the supporting actions of professionals affected by the crisis.

Interventions

longitunidal descriptive study

Sponsors

Regional Health Agency New Aquitaine
CollaboratorOTHER_GOV
Région Nouvelle Aquitaine
CollaboratorUNKNOWN
Centre Hospitalier Charles Perrens, Bordeaux
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Masking description

Data anonymisation: Participant timepoints data are identified and followed up through a token number

Intervention model description

Prospective Longitudinal Study by Self-administered Questionnaires

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* 18 years or more * hospital workers exposed to COVID-19 * consented to participate to the study * master the french langage * Understanding of type, objectives and study methology * accept an on-line evaluation * Benefit from health insurance

Exclusion criteria

* refuse to participate * pregnant or breastfeeding woman * Be under measure of legal protection: guardianship, curatorship or safeguard of justice.

Design outcomes

Primary

MeasureTime frameDescription
Changes in anxiety disorder overcomeinclusion, month 1, month 3, month 6, month 12GAD-7 score: \> 7 , the anxiety disorder status is supected, \[5; 9\] corresponds to anxiety evaluation: light \[10; 14\] corresponds to anxiety evaluation: moderate \> 15, corresponds to anxiety evaluation: severe

Secondary

MeasureTime frameDescription
Determination and collection of lived traumatic events typesinclusion, month 1, month 3, month 6, month 12Life Events Checklist for DSM-5 (LEC-5)
Posttraumatic stress disorder symptoms presence and measurmentinclusion, month 1, month 3, month 6, month 12Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5) PCL-5 score \> 32 indicate presence of Posttraumatic Stress Trouble (PST)
2-last-week mood assessmentinclusion, month 1, month 3, month 6, month 12Beck Depression Inventory - Fast Screen - France (BDI-FS FR) score \> 13 indicates presence of a depressive trouble
Identification of coping pattern to stressinclusion, month 1, month 3, month 6, month 12Coping Inventory for Stressful Situations (CISS) questionnaire Participant assess from 'little to a lot his tendency to adopt a task, emotion or behaviour based pattern
Burn out diagnosisinclusion, month 1, month 3, month 6, month 12MASLACH BURNOUT INVENTORY (MBI questionnaire) assessment of the 3 aspects from low to high * burn out feeling * deshumanisation * accomplishment at work
Self evaluation of state of healthinclusion, month 1, month 3, month 6, month 12considering the 4-last-weeks the participant will assess 8 under-scales for score 0 to 100 (favourable)
Psycho active drugs intakes and level of intake over the last monthinclusion, month 1, month 3, month 6, month 12selection of the drug and level of intake will n\*be assessed 'none', new, increasing, constant
Evaluation of the CUMP support to health professionnalsinclusion, month 1, month 3, month 6, month 12answer yes' or no support has been contacted already or since the last study assessement

Contacts

Primary ContactHelen SAVARIEAU, MS
hsavarieau@ch-perrens.fr+33 556 563 556
Backup ContactCharles Henry MARTIN, MD
cmartin@ch-perrens.fr+33 556 563 147

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026